Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Macitentan in pulmonary hypertension due to left ventricular dysfunction

JL. Vachiéry, M. Delcroix, H. Al-Hiti, M. Efficace, M. Hutyra, G. Lack, K. Papadakis, LJ. Rubin,

. 2018 ; 51 (2) : . [pub] 20180207

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028576

The MELODY-1 study evaluated macitentan for pulmonary hypertension because of left heart disease (PH-LHD) in patients with combined post- and pre-capillary PH.63 patients with PH-LHD and diastolic pressure gradient ≥7 mmHg and pulmonary vascular resistance (PVR) >3WU were randomised to macitentan 10 mg (n=31) or placebo (n=32) for 12 weeks. The main end-point assessed a composite of significant fluid retention (weight gain ≥5% or ≥5 kg because of fluid overload or parenteral diuretic administration) or worsening in New York Heart Association functional class from baseline to end of treatment. Exploratory end-points included changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) and haemodynamics at week 12.Seven macitentan-treated and four placebo-treated patients experienced significant fluid retention/worsening functional class; treatment difference, 10.08% (95% CI -15.07-33.26; p=0.34). The difference, driven by the fluid retention component, was apparent within the first month. At week 12, versus placebo, the macitentan group showed no change in PVR, mean right atrial pressure or pulmonary arterial wedge pressure; a non-significant increase in cardiac index (treatment effect 0.4 (95% CI 0.1-0.7) L·min-1·m-2) and decrease in NT-proBNP (0.77 (0.55-1.08)) was observed. Adverse events and serious adverse events were numerically more frequent with macitentan versus placebo.Macitentan-treated patients were quantitatively more likely to experience significant fluid retention versus placebo. Macitentan resulted in no significant changes in any exploratory end-points.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028576
003      
CZ-PrNML
005      
20190819095829.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1183/13993003.01886-2017 $2 doi
035    __
$a (PubMed)29437943
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vachiéry, Jean-Luc $u Dept of Cardiology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium jeanluc.vachiery@erasme.ulb.ac.be.
245    10
$a Macitentan in pulmonary hypertension due to left ventricular dysfunction / $c JL. Vachiéry, M. Delcroix, H. Al-Hiti, M. Efficace, M. Hutyra, G. Lack, K. Papadakis, LJ. Rubin,
520    9_
$a The MELODY-1 study evaluated macitentan for pulmonary hypertension because of left heart disease (PH-LHD) in patients with combined post- and pre-capillary PH.63 patients with PH-LHD and diastolic pressure gradient ≥7 mmHg and pulmonary vascular resistance (PVR) >3WU were randomised to macitentan 10 mg (n=31) or placebo (n=32) for 12 weeks. The main end-point assessed a composite of significant fluid retention (weight gain ≥5% or ≥5 kg because of fluid overload or parenteral diuretic administration) or worsening in New York Heart Association functional class from baseline to end of treatment. Exploratory end-points included changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) and haemodynamics at week 12.Seven macitentan-treated and four placebo-treated patients experienced significant fluid retention/worsening functional class; treatment difference, 10.08% (95% CI -15.07-33.26; p=0.34). The difference, driven by the fluid retention component, was apparent within the first month. At week 12, versus placebo, the macitentan group showed no change in PVR, mean right atrial pressure or pulmonary arterial wedge pressure; a non-significant increase in cardiac index (treatment effect 0.4 (95% CI 0.1-0.7) L·min-1·m-2) and decrease in NT-proBNP (0.77 (0.55-1.08)) was observed. Adverse events and serious adverse events were numerically more frequent with macitentan versus placebo.Macitentan-treated patients were quantitatively more likely to experience significant fluid retention versus placebo. Macitentan resulted in no significant changes in any exploratory end-points.
650    _2
$a senioři $7 D000368
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a plicní hypertenze $x farmakoterapie $x patofyziologie $7 D006976
650    _2
$a internacionalita $7 D038622
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a natriuretický peptid typu B $x účinky léků $x metabolismus $7 D020097
650    _2
$a peptidové fragmenty $x účinky léků $x metabolismus $7 D010446
650    _2
$a plicní tlak v zaklínění $x účinky léků $7 D011669
650    _2
$a pyrimidiny $x aplikace a dávkování $7 D011743
650    _2
$a sulfonamidy $x aplikace a dávkování $7 D013449
650    _2
$a výsledek terapie $7 D016896
650    _2
$a cévní rezistence $x účinky léků $7 D014655
650    _2
$a dysfunkce levé srdeční komory $x komplikace $7 D018487
650    _2
$a test chůzí $7 D000070857
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Delcroix, Marion $u Dept of Respiratory Diseases, KU Leuven - University Hospitals of Leuven, Leuven, Belgium.
700    1_
$a Al-Hiti, Hikmet $u Dept of Cardiology, Institute of Clinical and Experimental Medicine-IKEM, Prague, Czech Republic.
700    1_
$a Efficace, Michela $u Dept of Clinical Development - Biostatistics, Actelion Pharmaceuticals Italia, Imperia, Italy.
700    1_
$a Hutyra, Martin $u Dept of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Lack, Gabriela $u Dept of Global Clinical Science & Epidemiology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Papadakis, Kelly $u Dept of Clinical Research, Actelion Clinical Research Inc., Cherry Hill, NJ, USA.
700    1_
$a Rubin, Lewis J $u Division of Pulmonary and Critical Care Medicine, University of California San Diego, La Jolla, CA, USA.
773    0_
$w MED00001660 $t The European respiratory journal $x 1399-3003 $g Roč. 51, č. 2 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29437943 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190819100103 $b ABA008
999    __
$a ok $b bmc $g 1433725 $s 1067036
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 51 $c 2 $e 20180207 $i 1399-3003 $m The European respiratory journal $n Eur Respir J $x MED00001660
LZP    __
$a Pubmed-20190813
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace